ARBINOXA ORAL SOLUTION Rx
Generic Name and Formulations:
Carbinoxamine maleate 4mg/5mL; bubble gum flavor.
Indications for ARBINOXA ORAL SOLUTION:
Allergic (seasonal and perennial) and vasomotor rhinitis, conjunctivitis, urticaria, angioedema, reactions to blood. Adjunct in anaphylaxis. Dermatographism.
4–8mg 3–4 times daily.
<2yrs: contraindicated. 2–5yrs: 0.2–0.4mg/kg/day in 3–4 divided doses. 6–11yrs: 2–4mg 3–4 times daily.
Children <2yrs old. Concomitant MAOIs. Nursing mothers.
Not for treating lower respiratory tract symptoms, including asthma. Narrow angle glaucoma. Peptic ulcer. GI or GU obstruction. Increased intraocular pressure. Hyperthyroidism. Cardiovascular disease. Hypertension. Elderly. Pregnancy (Cat.C).
CNS depression potentiated by alcohol (avoid), other CNS depressants. MAOIs potentiate anticholinergic effects.
Sedation, sleepiness, dizziness, disturbed coordination, GI upset, thickening of bronchial secretions, anticholinergic effects, excitability in children.
Tabs—100; Oral soln—16oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- Higher Radiation Dose May Not Improve Prostate Cancer Outcomes
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches